
Invivyd, Inc.
93
Recent developments include quarterly financial results reporting losses and revenue below expectations, completion of enrollment in Phase 3 LIBERTY trial for VYD2311, leadership changes with appointment of new CEO, and ongoing clinical progress with FDA Fast Track designations.
- Invivyd reported a net loss of $33.5 million and revenue of $15.4 million for Q3 2026, with EPS of -$0.10 [N1,S2].
- The company completed enrollment in the Phase 3 LIBERTY trial of VYD2311 for COVID-19 prevention [N1].
- Marc Elia was named CEO and new directors were added to the board [N5].
- Invivyd continues to advance VYD2311 through clinical development with FDA Fast Track designation for prevention of COVID-19 [N4].
- The company reported Q2 2026 losses and revenue below expectations earlier in the year [N6].
Invivyd, Inc. focuses on developing monoclonal antibody therapies for prevention and treatment of serious viral infectious diseases, starting with COVID-19. Its lead product, PEMGARDA, received FDA Emergency Use Authorization in March 2024 for pre-exposure prophylaxis in immunocompromised individuals. The company is advancing VYD2311, a next-generation monoclonal antibody candidate, through Phase 3 clinical trials (DECLARATION and LIBERTY) with FDA Fast Track designation. Invivyd employs continuous viral variant surveillance and antibody engineering to address viral evolution and resistance. The company also targets other infectious diseases such as RSV and measles. Manufacturing and clinical activities are conducted through partnerships and contract organizations. As of September 30, 2026, Invivyd reported $15.4 million in revenue and a net loss of $33.5 million, with strong liquidity metrics.
Invivyd, Inc. is a biopharmaceutical company specializing in monoclonal antibody therapies targeting serious viral infectious diseases, primarily COVID-19. Its first authorized product, PEMGARDA, holds FDA Emergency Use Authorization for pre-exposure prophylaxis in immunocompromised patients. The company is advancing VYD2311, a next-generation antibody candidate in Phase 3 trials with FDA Fast Track designation. Invivyd maintains strong liquidity with $126.4 million cash as of September 30, 2026, and reported $15.4 million revenue and a net loss of $33.5 million for Q3 2026. Recent developments include leadership changes and ongoing clinical progress for VYD2311. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Invivyd's focused monoclonal antibody platform addresses unmet needs in prevention of COVID-19 for immunocompromised populations, supported by FDA Emergency Use Authorization for PEMGARDA and Fast Track designation for VYD2311. The company's continuous viral variant monitoring and antibody engineering capabilities may enable adaptation to emerging variants. Expansion into other viral diseases such as RSV and measles diversifies the pipeline. Strong liquidity supports ongoing clinical development and commercialization efforts. Strategic partnerships for manufacturing and discovery enhance operational capabilities.
Invivyd faces risks from the evolving SARS-CoV-2 virus, which may reduce the effectiveness of monoclonal antibody therapies and impact regulatory authorizations. The company reported net losses and revenue below expectations in recent quarters, indicating challenges in commercial execution or market adoption. Clinical development of VYD2311 and other candidates carries inherent risks including trial outcomes and regulatory approvals. Dependence on third-party partners for manufacturing and trials may introduce operational risks. Competitive pressures from other COVID-19 therapeutics and vaccines may limit market opportunities.
Invivyd's moat derives from its specialized monoclonal antibody platform focused on viral infectious diseases, particularly COVID-19, with a product authorized under FDA EUA and a pipeline of next-generation antibodies designed to address viral evolution and resistance. The company's continuous viral variant surveillance, antibody engineering capabilities, and partnership with Adimab provide technological differentiation. Regulatory Fast Track designations and established manufacturing partnerships support expedited development and supply. However, the competitive landscape includes other biopharmaceutical firms developing antibody therapies and vaccines, and the evolving nature of viral variants poses ongoing challenges.
• Viral Evolution Risk: Emergence of SARS-CoV-2 variants with resistance to monoclonal antibodies could reduce product effectiveness and impact regulatory authorizations.
• Clinical Development Risk: Phase 3 clinical trials for VYD2311 and other candidates may not demonstrate sufficient safety or efficacy to support regulatory approval.
• Commercial Execution Risk: Challenges in market adoption, reimbursement, and competition may affect revenue generation and profitability.
• Operational Risk: Reliance on third-party contract organizations for manufacturing and clinical trials may pose risks related to supply chain, quality, and timelines.
Business trends: Continued advancement of monoclonal antibody candidates targeting COVID-19 and expansion into other viral diseases, with ongoing regulatory engagement and variant surveillance.
Execution milestones: Completion and reporting of Phase 3 clinical trials for VYD2311, potential regulatory submissions, and commercial launch execution for PEMGARDA.
Key risks: Viral variant resistance impacting product efficacy and authorization, clinical trial outcomes, commercial adoption challenges, and reliance on third-party partners.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Invivyd, Inc. is a biopharmaceutical company focused on discovery, development, and commercialization of monoclonal antibody therapies for prevention and treatment of serious viral infectious diseases, starting with COVID-19 caused by SARS-CoV-2 [S1].
- The company's first authorized product is PEMGARDA (pemivibart), an investigational monoclonal antibody granted Emergency Use Authorization (EUA) by the FDA in March 2024 for pre-exposure prophylaxis of COVID-19 in immunocompromised adults and adolescents [S1].
- PEMGARDA's EUA is conditional on the prevalence of variants susceptible to the antibody and is authorized only during the COVID-19 emergency declaration [S1].
- Invivyd is developing VYD2311, a next-generation monoclonal antibody candidate for COVID-19 prevention, with Phase 1/2 clinical trials completed showing positive safety and pharmacokinetics data [S1].
- The company initiated Phase 3 clinical trials for VYD2311, including DECLARATION and LIBERTY trials, designed to evaluate safety, efficacy, and immunogenicity, with FDA Fast Track designation granted for prevention of COVID-19 in high-risk individuals [S1].
- Invivyd has a strategy to develop broadly neutralizing antibodies with reduced risk of viral escape, leveraging continuous variant surveillance and antibody engineering capabilities, including a partnership with Adimab for antibody discovery and engineering [S1].
- The company is expanding its pipeline to other viral infectious diseases such as respiratory syncytial virus (RSV) and measles, with candidates VBY329 for RSV and plans for a measles candidate [S1].
- Invivyd relies on partnerships and contract organizations for discovery, clinical trials, manufacturing, and testing, including WuXi Biologics for manufacturing of PEMGARDA and VYD2311 [S1].
- Financial snapshot as of September 30, 2026, shows cash and equivalents of $126.4 million, current assets of $147.8 million, current liabilities of $26.8 million, resulting in a current ratio of 5.51 and cash ratio of 4.71, indicating strong liquidity [S2].
- For the three months ended September 30, 2026, Invivyd reported revenue of $15.4 million and a net loss of $33.5 million, with basic and diluted EPS of -$0.10 [S2].
- Recent news reports indicate Invivyd reported Q3 losses and revenue below estimates, completed enrollment in Phase 3 LIBERTY trial of VYD2311, and announced leadership changes including naming Marc Elia as CEO [N1,N5,N6].
- The company has received FDA Fast Track designation for VYD2311 and is pursuing a potential Biologics License Application (BLA) submission pathway based on Phase 3 trial data [S1,N4].
Generated 2026-11-16
- S1 | 2026-03-05 | 10-K
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-11-16 | www.nasdaq.com | Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/invivyd-inc-ivvd-reports-q3-loss-misses-revenue-estimates
- N2 | 2026-11-13 | www.nasdaq.com | Milestone Pharmaceuticals (MIST) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/milestone-pharmaceuticals-mist-reports-q3-loss-beats-revenue-estimates
- N3 | 2026-11-10 | www.nasdaq.com | TELA Bio, Inc. (TELA) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/tela-bio-inc-tela-reports-q3-loss-beats-revenue-estimates
- N4 | 2026-10-02 | www.nasdaq.com | Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data | https://www.nasdaq.com/articles/weekly-buzz-ew-abbv-mirm-score-fda-wins-azn-nvo-strike-deals-lly-kod-report-data
- N5 | 2026-09-01 | www.nasdaq.com | Invivyd Names Chairman Marc Elia CEO, Adds New Directors | https://www.nasdaq.com/articles/invivyd-names-chairman-marc-elia-ceo-adds-new-directors
- N6 | 2026-08-13 | www.nasdaq.com | Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/invivyd-inc-ivvd-reports-q2-loss-lags-revenue-estimates
- N7 | 2026-08-12 | www.nasdaq.com | RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/renovorx-inc-rnxt-reports-q2-loss-beats-revenue-estimates
- N8 | 2026-08-06 | www.nasdaq.com | SkinHealth Systems Inc. (SKIN) Reports Q2 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/skinhealth-systems-inc-skin-reports-q2-loss-lags-revenue-estimates
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


